258 related articles for article (PubMed ID: 22479369)
1. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
[TBL] [Abstract][Full Text] [Related]
2. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population.
Wu W; Zhang W; Qiao R; Chen D; Wang H; Wang Y; Zhang S; Gao G; Gu A; Shen J; Qian J; Fan W; Jin L; Han B; Lu D
Clin Cancer Res; 2009 Jun; 15(11):3889-95. PubMed ID: 19458053
[TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
4. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
[TBL] [Abstract][Full Text] [Related]
5. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
6. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
7. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
[TBL] [Abstract][Full Text] [Related]
8. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
9. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
[TBL] [Abstract][Full Text] [Related]
11. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Qiu M; Yang X; Hu J; Ding X; Jiang F; Yin R; Xu L
PLoS One; 2013; 8(8):e72251. PubMed ID: 23977265
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
Zhang L; Ma W; Li Y; Wu J; Shi GY
Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
15. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
17. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Li XD; Han JC; Zhang YJ; Li HB; Wu XY
Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
[TBL] [Abstract][Full Text] [Related]
18. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
19. [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Zhang XR; Xu BH; Lin DX
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):196-9. PubMed ID: 16875604
[TBL] [Abstract][Full Text] [Related]
20. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
